Has developed a proprietary device (“IonojetTM”) that generates nitric oxide (“NO”) from atmospheric air in the form of a high-energy plasma/NO stream and delivers it to targeted locations of the body.

The plasma/NO stream has been shown in investigations to date:

(i)to be non-toxic

(ii) to generate NO activity up to 3 cm below the skin

(iii) to stimulate sustained biological activity in tissue for up to an hour after delivery of the therapy, and

(iv) to penetrate and disrupt biofilm

Has identified over 40 target indications in seven clinical areas based on NO’s recognized ability to:

• Increase blood flow
• Destroy pathogens (bacterial, viral and fungal)
• Regenerate tissue
• Control pain and inflammation

Has completed a dose-ranging feasibility clinical trial in the U.S. for initial target indication (Diabetic Foot Ulcers, “DFU”) to identify optimal dose & demonstrate preliminary safety/efficacy data for the device.

• Has completed PoC studies in certain target indications
• Intends to initiate PoC studies in a number of additional indications

For more details about technology: Click Here

White refined sugar is almost pure sucrose. This sucrose is consistently shown in research to be quickly absorbed into the blood stream causing rises in blood sugar levels. This in turn has contributed to the global obesity and diabetes crisis.

The Nucane™ specification of raw sugar is scientifically tested to ensure that this absorption is reduced.What the unique Nucane™ process achieves is to retain at a high level the natural organics, antioxidants and polyphenols that exist in raw sugar cane, delivering a carbohydrate that is less processed, less refined, and which has been demonstrated scientifically to reduce the metabolism of sugar into the blood stream when consumed. This means that it is a low glycemic sugar when tested to the internationally agreed ISO 26442:2010 method.Just as importantly, our technology system ensures that Nucane™ is precise and consistent at industrial scale in primary sugar mills around the world. By eliminating the refining process and applying the Nucane technology at sugar mills, Nucane™ is a less processed, less refined, high in polyphenols specification of raw sugar which has been tested to be low glycemic to international standards.

For more details about technology: Click here

WELLNESS Screening/Monitoring

Diabetes

Diagnosed and undiagnosed diabetes in the United States, all ages, 2012, Total: 29.1 million people or 9.3% of the population have diabetes. Diagnosed: 21.0 million people. Undiagnosed: 8.1 million people. (27.8% of people with diabetes are undiagnosed)

NASH/NAFLD

Prevalence of NAFLD and NASH is higher than estimated previously. Hispanics and patients with diabetes are at greatest risk for both NAFLD and NASH. Up to 80% of obese people have the disease. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD, and is regarded as a major cause of cirrhosis of the liver of unknown cause. About 12 to 25% of people in the United States has NAFLD. While NASH affects between 2 to 5% of people in the United States.

Cholesterol

Percent of adults age 20 years and over with high serum total cholesterol (greater than or equal to 240 mg/dL): 13.4% (2009-2012)

Gout

Gout prevalence swells in U.S. over last two decades; Increase in obesity and hypertension are likely contributors. Prevalence of gout in the United States has risen over the last twenty years and now affects 8.3 million Americans.

For more details about technology: Click here